Prostate Cancer | Drug Pipeline update.
Newly approved therapies shift treatment dynamics for castration-resistant disease
By Colin White, Lead Analyst
15 August 2013
I am the Lead Analyst for Oncology at Datamonitor Healthcare. I joined Datamonitor in 2009, having previously worked as ...
Read full bio
A review of candidates in development for prostate cancer across the US, Japan, France, Germany, Italy, Spain, and the UK, highlighting key trends, as well as analyses of clinical trial design, and innovative early-stage projects.
In-depth analysis of late-stage pipeline drugs including new clinical data.
The development of late-stage pipeline candidates Sprycel and Orteronel hangs in the balance after Phase III trial failures.
Targeted therapies dominate the prostate cancer pipeline. The advancement in understanding the molecular basis of prostate cancer has exposed new targets, but companies must identify the correct ones to improve the chances of success.
Clinical trial design must demonstrate the clinical efficacy of novel therapies. The selection of correct patient populations, trial duration, and endpoints is becoming increasingly important in the era of target therapy development.
Datamonitor Healthcare has analyzed the prostate cancer pipeline using BioMedTracker. Novel and existing therapies have been benchmarked using the ideal target product profile and insight from key opinion leaders.
This is a Prostate Cancer analysis update from the Datamonitor Healthcare service, which provides regular and event-senstive research for key drugs and companies, treatment trends, patient populations and strategic issues.
- For more information on this research, please contact
- For current clients, please log-in to view the full analysis at: